EGFR mutations compromise hypoxia-associated radiation resistance through impaired replication fork–associated DNA damage repair

Mohammad Saki, Haruhiko Makino, Prashanthi Javvadi, Nozomi Tomimatsu, Liang Hao Ding, Jennifer E. Clark, Elaine Gavin, Kenichi Takeda, Joel Andrews, Debabrata Saha, Michael D. Story, Sandeep Burma, Chaitanya S. Nirodi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

EGFR signaling has been implicated in hypoxia-associated resistance to radiation or chemotherapy. Non–small cell lung carcinomas (NSCLC) with activating L858R or DE746-E750 EGFR mutations exhibit elevated EGFR activity and downstream signaling. Here, relative to wild-type (WT) EGFR, mutant (MT) EGFR expression significantly increases radiosensitivity in hypoxic cells. Gene expression profiling in human bronchial epithelial cells (HBEC) revealed that MT-EGFR expression elevated transcripts related to cell cycle and replication in aerobic and hypoxic conditions and downregulated RAD50, a critical component of nonhomologous end joining and homologous recombination DNA repair pathways. NSCLCs and HBEC with MT-EGFR revealed elevated basal and hypoxia-induced g-H2AX–associated DNA lesions that were coincident with replication protein A in the S-phase nuclei. DNA fiber analysis showed that, relative to WT-EGFR, MT-EGFR NSCLCs harbored significantly higher levels of stalled replication forks and decreased fork velocities in aerobic and hypoxic conditions. EGFR blockade by cetuximab significantly increased radiosensitivity in hypoxic cells, recapitulating MT-EGFR expression and closely resembling synthetic lethality of PARP inhibition.

Original languageEnglish (US)
Pages (from-to)1503-1516
Number of pages14
JournalMolecular Cancer Research
Volume15
Issue number11
DOIs
StatePublished - Nov 1 2017

Fingerprint

DNA Repair
DNA Damage
Radiation Tolerance
Radiation
Mutation
Epithelial Cells
Replication Protein A
Recombinational DNA Repair
DNA
Gene Expression Profiling
S Phase
Cell Cycle
Down-Regulation
Carcinoma
Drug Therapy
Lung
Hypoxia
Synthetic Lethal Mutations
Cetuximab

ASJC Scopus subject areas

  • Molecular Biology
  • Oncology
  • Cancer Research

Cite this

EGFR mutations compromise hypoxia-associated radiation resistance through impaired replication fork–associated DNA damage repair. / Saki, Mohammad; Makino, Haruhiko; Javvadi, Prashanthi; Tomimatsu, Nozomi; Ding, Liang Hao; Clark, Jennifer E.; Gavin, Elaine; Takeda, Kenichi; Andrews, Joel; Saha, Debabrata; Story, Michael D.; Burma, Sandeep; Nirodi, Chaitanya S.

In: Molecular Cancer Research, Vol. 15, No. 11, 01.11.2017, p. 1503-1516.

Research output: Contribution to journalArticle

Saki, Mohammad ; Makino, Haruhiko ; Javvadi, Prashanthi ; Tomimatsu, Nozomi ; Ding, Liang Hao ; Clark, Jennifer E. ; Gavin, Elaine ; Takeda, Kenichi ; Andrews, Joel ; Saha, Debabrata ; Story, Michael D. ; Burma, Sandeep ; Nirodi, Chaitanya S. / EGFR mutations compromise hypoxia-associated radiation resistance through impaired replication fork–associated DNA damage repair. In: Molecular Cancer Research. 2017 ; Vol. 15, No. 11. pp. 1503-1516.
@article{7c3f64414ea342f5b593a9d88a0119eb,
title = "EGFR mutations compromise hypoxia-associated radiation resistance through impaired replication fork–associated DNA damage repair",
abstract = "EGFR signaling has been implicated in hypoxia-associated resistance to radiation or chemotherapy. Non–small cell lung carcinomas (NSCLC) with activating L858R or DE746-E750 EGFR mutations exhibit elevated EGFR activity and downstream signaling. Here, relative to wild-type (WT) EGFR, mutant (MT) EGFR expression significantly increases radiosensitivity in hypoxic cells. Gene expression profiling in human bronchial epithelial cells (HBEC) revealed that MT-EGFR expression elevated transcripts related to cell cycle and replication in aerobic and hypoxic conditions and downregulated RAD50, a critical component of nonhomologous end joining and homologous recombination DNA repair pathways. NSCLCs and HBEC with MT-EGFR revealed elevated basal and hypoxia-induced g-H2AX–associated DNA lesions that were coincident with replication protein A in the S-phase nuclei. DNA fiber analysis showed that, relative to WT-EGFR, MT-EGFR NSCLCs harbored significantly higher levels of stalled replication forks and decreased fork velocities in aerobic and hypoxic conditions. EGFR blockade by cetuximab significantly increased radiosensitivity in hypoxic cells, recapitulating MT-EGFR expression and closely resembling synthetic lethality of PARP inhibition.",
author = "Mohammad Saki and Haruhiko Makino and Prashanthi Javvadi and Nozomi Tomimatsu and Ding, {Liang Hao} and Clark, {Jennifer E.} and Elaine Gavin and Kenichi Takeda and Joel Andrews and Debabrata Saha and Story, {Michael D.} and Sandeep Burma and Nirodi, {Chaitanya S.}",
year = "2017",
month = "11",
day = "1",
doi = "10.1158/1541-7786.MCR-17-0136",
language = "English (US)",
volume = "15",
pages = "1503--1516",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - EGFR mutations compromise hypoxia-associated radiation resistance through impaired replication fork–associated DNA damage repair

AU - Saki, Mohammad

AU - Makino, Haruhiko

AU - Javvadi, Prashanthi

AU - Tomimatsu, Nozomi

AU - Ding, Liang Hao

AU - Clark, Jennifer E.

AU - Gavin, Elaine

AU - Takeda, Kenichi

AU - Andrews, Joel

AU - Saha, Debabrata

AU - Story, Michael D.

AU - Burma, Sandeep

AU - Nirodi, Chaitanya S.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - EGFR signaling has been implicated in hypoxia-associated resistance to radiation or chemotherapy. Non–small cell lung carcinomas (NSCLC) with activating L858R or DE746-E750 EGFR mutations exhibit elevated EGFR activity and downstream signaling. Here, relative to wild-type (WT) EGFR, mutant (MT) EGFR expression significantly increases radiosensitivity in hypoxic cells. Gene expression profiling in human bronchial epithelial cells (HBEC) revealed that MT-EGFR expression elevated transcripts related to cell cycle and replication in aerobic and hypoxic conditions and downregulated RAD50, a critical component of nonhomologous end joining and homologous recombination DNA repair pathways. NSCLCs and HBEC with MT-EGFR revealed elevated basal and hypoxia-induced g-H2AX–associated DNA lesions that were coincident with replication protein A in the S-phase nuclei. DNA fiber analysis showed that, relative to WT-EGFR, MT-EGFR NSCLCs harbored significantly higher levels of stalled replication forks and decreased fork velocities in aerobic and hypoxic conditions. EGFR blockade by cetuximab significantly increased radiosensitivity in hypoxic cells, recapitulating MT-EGFR expression and closely resembling synthetic lethality of PARP inhibition.

AB - EGFR signaling has been implicated in hypoxia-associated resistance to radiation or chemotherapy. Non–small cell lung carcinomas (NSCLC) with activating L858R or DE746-E750 EGFR mutations exhibit elevated EGFR activity and downstream signaling. Here, relative to wild-type (WT) EGFR, mutant (MT) EGFR expression significantly increases radiosensitivity in hypoxic cells. Gene expression profiling in human bronchial epithelial cells (HBEC) revealed that MT-EGFR expression elevated transcripts related to cell cycle and replication in aerobic and hypoxic conditions and downregulated RAD50, a critical component of nonhomologous end joining and homologous recombination DNA repair pathways. NSCLCs and HBEC with MT-EGFR revealed elevated basal and hypoxia-induced g-H2AX–associated DNA lesions that were coincident with replication protein A in the S-phase nuclei. DNA fiber analysis showed that, relative to WT-EGFR, MT-EGFR NSCLCs harbored significantly higher levels of stalled replication forks and decreased fork velocities in aerobic and hypoxic conditions. EGFR blockade by cetuximab significantly increased radiosensitivity in hypoxic cells, recapitulating MT-EGFR expression and closely resembling synthetic lethality of PARP inhibition.

UR - http://www.scopus.com/inward/record.url?scp=85032833715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032833715&partnerID=8YFLogxK

U2 - 10.1158/1541-7786.MCR-17-0136

DO - 10.1158/1541-7786.MCR-17-0136

M3 - Article

VL - 15

SP - 1503

EP - 1516

JO - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 11

ER -